Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 485

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 485
---
1,996,912 | ​ | ​ | ​ | ​                | $ |   594,958 | ​ | ​ |
| Accrued legal expense    | ​ | ​ | ​                | ​ |    45,400 | ​ | ​ | ​ | ​                | ​ |   826,134 | ​ | ​ |
| Accrued expenses – other | ​ | ​ | ​                | ​ |   284,606 | ​ | ​ | ​ | ​                | ​ |    68,370 | ​ | ​ |
| ​                        | ​ | ​ | ​                | $ | 2,326,918 | ​ | ​ | ​ | ​                | $ | 1,489,462 | ​ | ​ |

F-44

TABLE OF CONTENTS

### IRIS ACQUISITION CORP

### NOTES TO FINANCIAL STATEMENTS

#### NOTE 6.   RELATED PARTY TRANSACTIONS

#### Founder Shares
In December 2020, the Sponsor paid $25,000, or approximately $0.004 per share, to cover certain offering costs in consideration for 5,750,000 Class B common stock, par value $0.0001 (the “Founder Shares”). In February 2021, the Company effected a stock dividend of 0.2 shares for each share of Class B common stock outstanding, resulting in the Sponsor holding an aggregate of 6,900,000 Founder Shares (up to an aggregate of 900,000 of which were subject to forfeiture depending on the extent to which the underwriters’ over-allotment option is exercised). All shares and associated amounts have been retroactively restated to reflect the stock dividend. As a result of the underwriters’ election to fully exercise their over-allotment option, the 900,000 shares were no longer subject to forfeiture.

On September 20, 2023, the Sponsor converted all of its Class B common stock on a one-for-one basis into Class A common stock. The Sponsor will not have any redemption rights in connection with the Converted Shares, and the Converted Shares will be subject to the restrictions on transfer entered into by the Sponsor in connection with the IPO.

The Sponsor has agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination and (B) the date on which the Company completes a liquidation, merger, capital stock exchange